212 related articles for article (PubMed ID: 38438856)
1. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR; Halpin M; Corbin DL; Asemelash Y; Sher S; Gordon BK; Whipp EC; Mitchell S; Harrington BK; Orwick S; Benrashid S; Goettl VM; Yildiz V; Mitchell AD; Cahn O; Mims AS; Larkin KTM; Long M; Blachly J; Woyach JA; Lapalombella R; Grieselhuber NR
Exp Hematol Oncol; 2024 Mar; 13(1):27. PubMed ID: 38438856
[TBL] [Abstract][Full Text] [Related]
2. Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.
Monteith AJ; Ramsey HE; Silver AJ; Brown D; Greenwood D; Smith BN; Wise AD; Liu J; Olmstead SD; Watke J; Arrate MP; Gorska AE; Fuller L; Locasale JW; Stubbs MC; Rathmell JC; Savona MR
Cancer Res; 2024 Apr; 84(7):1101-1114. PubMed ID: 38285895
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
6. Dinaciclib inhibits the growth of acute myeloid leukemia cells through either cell cycle-related or ERK1/STAT3/MYC pathways.
Teng CJ; Cheng PT; Cheng YC; Tsai JR; Chen MC; Lin H
Toxicol In Vitro; 2024 Apr; 96():105768. PubMed ID: 38135130
[TBL] [Abstract][Full Text] [Related]
7. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR
Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670
[TBL] [Abstract][Full Text] [Related]
8. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
9. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).
Djamai H; Berrou J; Dupont M; Coudé MM; Delord M; Clappier E; Marceau-Renaut A; Kaci A; Raffoux E; Itzykson R; Berthier C; Wu HC; Hleihel R; Bazarbachi A; de Thé H; Baruchel A; Gardin C; Dombret H; Braun T
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829934
[TBL] [Abstract][Full Text] [Related]
10. A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia.
Lee L; Hizukuri Y; Severson P; Powell B; Zhang C; Ma Y; Narahara M; Sumi H; Hernandez D; Rajkhowa T; Bollag G; Levis M
Haematologica; 2021 Apr; 106(4):1022-1033. PubMed ID: 33504139
[TBL] [Abstract][Full Text] [Related]
11. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine KA; Nechiporuk T; Bottomly D; Jeng S; McWeeney SK; Kaempf A; Corces MR; Majeti R; Tyner JW
Blood Cancer Discov; 2021 Sep; 2(5):518-531. PubMed ID: 34568834
[TBL] [Abstract][Full Text] [Related]
12. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia.
Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
[TBL] [Abstract][Full Text] [Related]
13. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
14. SOSTDC1 acts as a tumor inhibitor in acute myeloid leukemia by downregulating the Wnt/β-catenin pathway.
Li C; Wang M; Shi Y; Xin H
Environ Toxicol; 2022 Aug; 37(8):1934-1943. PubMed ID: 35442555
[TBL] [Abstract][Full Text] [Related]
15. Combined Application of Salinomycin and ATRA Induces Apoptosis and Differentiation of Acute Myeloid Leukemia Cells by Inhibiting WNT/β-Catenin Pathway.
Xi HM; Lu H; Weng XQ; Sheng Y; Wu J; Li L; Cai X
Anticancer Agents Med Chem; 2023; 23(9):1074-1084. PubMed ID: 36627782
[TBL] [Abstract][Full Text] [Related]
16. BET inhibitor resistance emerges from leukaemia stem cells.
Fong CY; Gilan O; Lam EY; Rubin AF; Ftouni S; Tyler D; Stanley K; Sinha D; Yeh P; Morison J; Giotopoulos G; Lugo D; Jeffrey P; Lee SC; Carpenter C; Gregory R; Ramsay RG; Lane SW; Abdel-Wahab O; Kouzarides T; Johnstone RW; Dawson SJ; Huntly BJ; Prinjha RK; Papenfuss AT; Dawson MA
Nature; 2015 Sep; 525(7570):538-42. PubMed ID: 26367796
[TBL] [Abstract][Full Text] [Related]
17. TNKS inhibitors potentiate proliferative inhibition of BET inhibitors via reducing β-Catenin in colorectal cancer cells.
Wu Q; Xuan YF; Su AL; Bao XB; Miao ZH; Wang YQ
Am J Cancer Res; 2022; 12(3):1069-1087. PubMed ID: 35411247
[TBL] [Abstract][Full Text] [Related]
18. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
19. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
20. DIXDC1 promotes the growth of acute myeloid leukemia cells by upregulating the Wnt/β-catenin signaling pathway.
Xin H; Li C; Wang M
Biomed Pharmacother; 2018 Nov; 107():1548-1555. PubMed ID: 30257373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
